Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Gastric Cancer

Free Subscription Articles published in BMC Cancer Retrieve available abstracts of 208 articles: HTML format

Single Articles

September 2025
1. SUN Y, Hou L, Zhao E
   Correction: Short-term outcomes of laparoscopic D2 lymphadenectomy versus D2 lymphadenectomy plus complete mesogastric excision in distal gastric cancer patients with high body mass index.
   BMC Cancer. 2025;25:1420.
   PubMed    
   
   
   August 2025
2. GAO X, Li Z, Yuan J, Mei X, et al
   Comparison of short- and long-term outcomes among total laparoscopic, laparoscopic-assisted, and open total gastrectomies for advanced gastric cancer patients after neoadjuvant chemotherapy: a multicenter retrospective cohort study.
   BMC Cancer. 2025;25:1401.
   PubMed     Abstract available
   
   
   
3. SHANSHAN W, Lian W, Lu D, Liping L, et al
   Best practices for home nutritional management in postoperative gastric cancer patients: an evidence summary.
   BMC Cancer. 2025;25:1399.
   PubMed     Abstract available
   
   
   
4. ZHANG R, Chen X, Chen G, Zhao Z, et al
   Novel surveillance protocol for gastric cancer based on CEA: a high-volume multi-center study.
   BMC Cancer. 2025;25:1396.
   PubMed     Abstract available
   
   
   
5. ZENG T, Ling X, Chen S, Yang J, et al
   Prognostic value of nutritional risk assessment indices in patients with digestive system tumors.
   BMC Cancer. 2025;25:1385.
   PubMed     Abstract available
   
   
   
6. WU H, Shu W, Ding Y, Li Q, et al
   The immune signatures predict gastric/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapy.
   BMC Cancer. 2025;25:1369.
   PubMed     Abstract available
   
   
   
7. YUE HY, Yang XT, Zhang JC, Zhou P, et al
   Impacts of omega-3 fatty acids intervention on immune functions and clinical outcomes in surgical gastric cancer patients: a systematic review and trial sequential meta-analysis.
   BMC Cancer. 2025;25:1366.
   PubMed     Abstract available
   
   
   
8. WANG L, Yang F, Dong Q, Tung TH, et al
   Anti-PD-1 therapy achieves favorable outcome in gastric cancer combined with chronic hepatitis B.
   BMC Cancer. 2025;25:1354.
   PubMed     Abstract available
   
   
   
9. ZHAI XM, Yang YQ, Lin L, Luo HC, et al
   CircMORC1 downregulated in plasma EVs promotes gastric cancer cell proliferation and invasion via miR-103a-1-5p sponging.
   BMC Cancer. 2025;25:1313.
   PubMed     Abstract available
   
   
   
10. HUANG Y, Huang Z, Hou W, Wang C, et al
    Cachexia index as a biomarker for cancer cachexia and quality of life in patients with gastric cancer.
    BMC Cancer. 2025;25:1293.
    PubMed     Abstract available
    
    
    
11. LUAN X, Han X, Wang Z, Zhao L, et al
    Heterogeneity of metastatic gastric cancer: solitary non-regional lymph node metastasis and solitary lung metastasis showed better survival outcomes than other metastatic patterns.
    BMC Cancer. 2025;25:1287.
    PubMed     Abstract available
    
    
    
12. XIA S, Xia Y, Liu T, Luo Y, et al
    Application of deep learning models in gastric cancer pathology image analysis: a systematic scoping review.
    BMC Cancer. 2025;25:1257.
    PubMed     Abstract available
    
    
    July 2025
13. LIN CR, Wang MX, Guo XY, Huang YX, et al
    Global trends and sociodemographic inequalities in smoking and high-salt diet attributable to gastric cancer: a secondary analysis based on the global burden of disease 2021 study.
    BMC Cancer. 2025;25:1248.
    PubMed     Abstract available
    
    
    
14. CHEN Y, Liu D, Wang Z, Lin Y, et al
    Machine learning-based dynamic CEA trajectory and prognosis in gastric cancer.
    BMC Cancer. 2025;25:1221.
    PubMed     Abstract available
    
    
    
15. WEI J, Xue S, Du X, Dai Y, et al
    DNMT1 blocks SOX21-repressed CKS2 transcription to promote gastric cancer progression.
    BMC Cancer. 2025;25:1182.
    PubMed    
    
    
    
16. TANPRASERT P, Chakrabandhu B, Yodkeeree S, Dejkriengkraikul Limtrakul P, et al
    Survival benefit of conversion surgery after intravenous 5-fluorouracil-based chemotherapy in unresectable advanced gastric cancer: a retrospective cohort study.
    BMC Cancer. 2025;25:1160.
    PubMed     Abstract available
    
    
    
17. YANG L, Zhang Q, Zhang H, Shi H, et al
    Nutrition impact symptoms as prognostic indicators in gastric cancer: the role of quality of life and survival outcomes.
    BMC Cancer. 2025;25:1037.
    PubMed     Abstract available
    
    
    
18. GUO F, Wang D, Zhang L, Fang Y, et al
    Efficacy and safety of anti-PD-1 antibodies plus small molecule anti-angiogenic drugs and chemotherapy in gastric cancer peritoneal metastasis: a multicenter real-world study.
    BMC Cancer. 2025;25:1028.
    PubMed     Abstract available
    
    
    
19. YANG J, Xu W, Wang S, Yu Z, et al
    Comprehensive multi-omics pan-cancer analysis revealed EGFLAM as a potential prognostic and immune infiltration-associated biomarker.
    BMC Cancer. 2025;25:1109.
    PubMed     Abstract available
    
    
    
20. HUANG Y, Hu Y
    Impact of helicobacter pylori infection on the efficacy of ICIs in gastric cancer.
    BMC Cancer. 2025;25:1101.
    PubMed     Abstract available
    
    
    
21. CHEN Q, Yao Z, Duan J, Zhang Y, et al
    The levels of plasma MiR-9 and MiR-106a are associated with the development of peritoneal carcinomatosis in patients with gastric cancer.
    BMC Cancer. 2025;25:1090.
    PubMed     Abstract available
    
    
    June 2025
22. MA Y, Li Y, Lin Z, Wang J, et al
    Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis.
    BMC Cancer. 2025;25:1010.
    PubMed     Abstract available
    
    
    
23. TUOHUTI T, Abulizi K, Li T
    Short-term outcomes of robotic vs. laparoscopic surgery for gastric cancer after neoadjuvant therapy: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:1002.
    PubMed     Abstract available
    
    
    
24. WANG Y, Li Y, Guo Y, Jiang S, et al
    Lipid accumulation product and visceral adiposity index as independent predictors of long-term survival after gastric cancer immunotherapy.
    BMC Cancer. 2025;25:1009.
    PubMed     Abstract available
    
    
    
25. SONG S, Zhang X, Cui P, He W, et al
    Plasma cfDNA multi-omic biomarkers profiling for detection and stratification of gastric carcinoma.
    BMC Cancer. 2025;25:1003.
    PubMed     Abstract available
    
    
    
26. LAN N, Lai M, Gao Y, Wang X, et al
    The mediating role of postoperative blood glucose in the relationship between body composition and overall survival in non-diabetic gastric cancer patients.
    BMC Cancer. 2025;25:995.
    PubMed    
    
    
    
27. WU YY, Lee LC, Zeng H, Gu Y, et al
    Synergistic effects of PD-1 antibody and chemotherapy followed by surgery-centric local treatment in patients with limited-metastatic gastric or gastroesophageal adenocarcinoma (ROSETTE trial): an open-label, single-center, randomized phase 2 trial.
    BMC Cancer. 2025;25:981.
    PubMed     Abstract available
    
    
    May 2025
28. DU K, Hu W, Gao S, Gan J, et al
    Identification of multiomics and immune infiltration-associated biomarkers for early gastric cancer: a machine learning-based diagnostic model development study.
    BMC Cancer. 2025;25:972.
    PubMed     Abstract available
    
    
    
29. ZHANG M, Bai L, Chen J, Meng Q, et al
    Clinical benefit of continuation of PD-1 inhibitors after progression on first-line chemoimmunotherapy in metastatic gastric cancer and biomarker exploration.
    BMC Cancer. 2025;25:935.
    PubMed     Abstract available
    
    
    
30. ZHANG B, Chen Y, Gu X, Zheng Y, et al
    Fucosyltransferase 11 restrains ferroptosis via upregulation GPX4 expression in gastric cancer.
    BMC Cancer. 2025;25:923.
    PubMed     Abstract available
    
    
    
31. LI H, Chen H, Zhao T, Zhang W, et al
    CD2AP shapes a stromal reduced tumor microenvironment and contributes to immunotherapy in gastric cancer.
    BMC Cancer. 2025;25:910.
    PubMed     Abstract available
    
    
    
32. ZHANG C, Wang K, Zhang Z, Zhao X, et al
    Safety and short?term outcomes of a modified tubular esophagogastrostomy versus double tract reconstruction after proximal gastrectomy: a propensity score matching analysis.
    BMC Cancer. 2025;25:908.
    PubMed     Abstract available
    
    
    
33. FAN S, Jiang H, Xu Q, Shen J, et al
    Risk factors for pneumonia after radical gastrectomy for gastric cancer: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:840.
    PubMed     Abstract available
    
    
    
34. LING T, Zuo Z, Huang M, Ma J, et al
    Stacking classifiers based on integrated machine learning model: fusion of CT radiomics and clinical biomarkers to predict lymph node metastasis in locally advanced gastric cancer patients after neoadjuvant chemotherapy.
    BMC Cancer. 2025;25:834.
    PubMed     Abstract available
    
    
    April 2025
35. RAFIEPOOR H, Banoei MM, Ghorbankhanloo A, Muhammadnejad A, et al
    Exploring the potential of machine learning in gastric cancer: prognostic biomarkers, subtyping, and stratification.
    BMC Cancer. 2025;25:809.
    PubMed     Abstract available
    
    
    
36. LIU G, Cao S, Liu X, Tian Y, et al
    Effect of perioperative probiotic supplements on the short-term clinical outcomes of patients undergoing laparoscopic or robotic radical gastrectomy after neoadjuvant chemotherapy: Study protocol for a multicenter randomized controlled trial (GISSG202
    BMC Cancer. 2025;25:776.
    PubMed     Abstract available
    
    
    
37. GUO H, Chen S, Zheng T, Ding P, et al
    Association of low skeletal muscle mass and radiodensity with clinical outcomes in patients undergoing robotic radical gastric cancer surgery: a population-based retrospective cohort study.
    BMC Cancer. 2025;25:741.
    PubMed     Abstract available
    
    
    
38. BU S, Wang S, Wang T, Xing H, et al
    Efficacy and safety of XELOX combined with neoadjuvant radiotherapy versus neoadjuvant chemotherapy in locally advanced gastric cancer.
    BMC Cancer. 2025;25:731.
    PubMed     Abstract available
    
    
    
39. FU M, Wang X, Zhou J, Wang J, et al
    Incidence and risk factors of sarcopenia in gastric cancer patients: a meta-analysis and systematic review.
    BMC Cancer. 2025;25:711.
    PubMed     Abstract available
    
    
    
40. WU GF, He CH, Xi WT, Zhai WB, et al
    Sarcopenia defined by the global leadership initiative in sarcopenia (GLIS) consensus predicts adverse postoperative outcomes in patients undergoing radical gastrectomy for gastric cancer: analysis from a prospective cohort study.
    BMC Cancer. 2025;25:679.
    PubMed     Abstract available
    
    
    
41. BABA K, Suzuki N, Imamura CK, Booka E, et al
    A phase I/II trial evaluating the safety of increased-dose S- 1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancer.
    BMC Cancer. 2025;25:675.
    PubMed     Abstract available
    
    
    
42. ZHANG C, Wang T, Yuan J, Wang T, et al
    Potential predictive value of CD8A and PGF protein expression in gastric cancer patients treated with neoadjuvant immunotherapy.
    BMC Cancer. 2025;25:674.
    PubMed     Abstract available
    
    
    
43. SHAO Y, Chen C, Yu X, Yan J, et al
    Comprehensive analysis of scRNA-seq and bulk RNA-seq data via machine learning and bioinformatics reveals the role of lysine metabolism-related genes in gastric carcinogenesis.
    BMC Cancer. 2025;25:644.
    PubMed     Abstract available
    
    
    
44. NASCA V, Bergamo F, Foltran L, Antonuzzo L, et al
    Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical
    BMC Cancer. 2025;25:633.
    PubMed     Abstract available
    
    
    
45. KONG PF, Yan YH, Duan YT, Fang YT, et al
    Comparative genomic analysis of Helicobacter pylori isolates from gastric cancer and gastritis in China.
    BMC Cancer. 2025;25:628.
    PubMed     Abstract available
    
    
    
46. MA GF, Huang YY, Chen YC, Luo Z, et al
    Premature death patterns and trends of stomach cancer in Pudong, Shanghai: a population based study.
    BMC Cancer. 2025;25:618.
    PubMed     Abstract available
    
    
    
47. XIN X, Tang Y, Lu M, Huang J, et al
    Prognostic value of diffusion-weighted imaging to cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for patients with gastric cancer and peritoneal metastases.
    BMC Cancer. 2025;25:616.
    PubMed     Abstract available
    
    
    
48. ZHOU K, Hu X, Yang X, Wu Y, et al
    Clinicopathologic characteristics and prognostic factors of pure gastric neuroendocrine carcinoma patients undergoing radical surgery.
    BMC Cancer. 2025;25:606.
    PubMed     Abstract available
    
    
    
49. SUN Y, Wen L, Xiang W, Luo X, et al
    Added value of pretreatment CT-based Node-RADS score for predicting survival outcome of locally advanced gastric cancer: compared with clinical N stage.
    BMC Cancer. 2025;25:598.
    PubMed     Abstract available
    
    
    March 2025
50. WU Z, Wang X, Shi S, Kong D, et al
    Heterogeneity of T cells regulates tumor immunity mediated by Helicobacter pylori infection in gastric cancer.
    BMC Cancer. 2025;25:567.
    PubMed     Abstract available
    
    
    
51. LAN Y, Sun W, Zhong S, Xu Q, et al
    A risk prediction model for gastric cancer based on endoscopic atrophy classification.
    BMC Cancer. 2025;25:518.
    PubMed     Abstract available
    
    
    
52. HE QC, Huang ZN, Lv CB, Wu YH, et al
    Effect of Helicobacter pylori infection on survival outcomes of patients undergoing radical gastrectomy after neoadjuvant chemotherapy: a multicenter study in China.
    BMC Cancer. 2025;25:460.
    PubMed     Abstract available
    
    
    
53. GAN X, Jia Y, Shan F, Ying X, et al
    Comprehensive evaluation of tumor response better evaluates the efficacy of neoadjuvant chemotherapy and predicts the prognosis in gastric cancer - a post hoc analysis of a single-center randomized controlled trial.
    BMC Cancer. 2025;25:401.
    PubMed     Abstract available
    
    
    
54. KANWAL W, Narjis K, Musani S, Nancy F, et al
    Exploring Zanidatamab's efficacy across HER2-positive Malignancies: a narrative review.
    BMC Cancer. 2025;25:382.
    PubMed     Abstract available
    
    
    February 2025
55. XU M, Zhang Y, Zhao K, Jiang H, et al
    Prediction of pathological response to neoadjuvant immunochemotherapy with baseline and post-treatment (18)F-FDG PET imaging biomarkers in patients with locally advanced gastric cancer.
    BMC Cancer. 2025;25:378.
    PubMed     Abstract available
    
    
    
56. WANG L, Chang Y, Ma J, Qu W, et al
    Identifying high-risk candidates for prolonging progression-free survival in primary gastric carcinoma subject to "double invasion": an analytical approach utilizing lasso-cox regression.
    BMC Cancer. 2025;25:381.
    PubMed     Abstract available
    
    
    
57. PAN H, Sun H, Zuo Y, Zhao R, et al
    The prealbumin-CD19(+) index predicts surgical survival in patients with GC.
    BMC Cancer. 2025;25:359.
    PubMed     Abstract available
    
    
    
58. QIAO Y, Kang B, Zhang Y, Song J, et al
    Short- and long-term outcomes of robotic- versus laparoscopic-assisted early-onset gastric cancer: a propensity score-matched retrospective cohort study.
    BMC Cancer. 2025;25:361.
    PubMed     Abstract available
    
    
    
59. ENDO S, Higashida M, Fujiwara Y, Furuya K, et al
    Risk factors for postoperative pneumonia in older adults aged >/= 80 years with gastric cancer.
    BMC Cancer. 2025;25:342.
    PubMed     Abstract available
    
    
    
60. SUN Y, Hou L, Zhao E
    Short-term outcomes of laparoscopic D2 lymphadenectomy versus D2 lymphadenectomy plus complete mesogastric excision in distal gastric cancer patients with high body mass index.
    BMC Cancer. 2025;25:329.
    PubMed     Abstract available
    
    
    
61. GU Y, Ma X, Xin H, Xiang Z, et al
    Navigating life after gastric cancer surgery: a qualitative exploration of the dyadic patient-caregiver perspective on quality of life outcomes.
    BMC Cancer. 2025;25:288.
    PubMed     Abstract available
    
    
    
62. XU T, Huang J, Lin J, Liu Y, et al
    Correction: Site-specific immunoglobulin G N-glycosylation is associated with gastric cancer progression.
    BMC Cancer. 2025;25:292.
    PubMed    
    
    
    
63. OU JY, Liu Y, Zhang L, Luo TQ, et al
    Assessing the quality and integrating the evidence and strength of recommendations in the guidelines for gastric precancerous lesions.
    BMC Cancer. 2025;25:272.
    PubMed     Abstract available
    
    
    
64. LI X, Ding P, Wu J, Wu H, et al
    Preoperative sarcopenia and postoperative accelerated muscle loss negatively impact survival after resection of locally advanced gastric cancer.
    BMC Cancer. 2025;25:269.
    PubMed     Abstract available
    
    
    
65. YEKTAKOOSHALI MH, SobhZahedi M, Razavi Tousi SMT, Hamidi M, et al
    Correction: Astaxanthin-loaded PLGA nanoparticles inhibit survival of MKN-45 gastric cancer cell line modulating JAK2/STAT3/mTOR/PI3K pathway.
    BMC Cancer. 2025;25:258.
    PubMed    
    
    
    
66. XU T, Huang J, Lin J, Liu Y, et al
    Site-specific immunoglobulin G N-glycosylation is associated with gastric cancer progression.
    BMC Cancer. 2025;25:217.
    PubMed     Abstract available
    
    
    
67. ZENG Y, Chen Y, Zhu D, Xu J, et al
    Machine learning assisted radiomics in predicting postoperative occurrence of deep venous thrombosis in patients with gastric cancer.
    BMC Cancer. 2025;25:220.
    PubMed     Abstract available
    
    
    
68. HIRANO H, Takahashi N, Amanuma Y, Suzuki N, et al
    Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE)
    BMC Cancer. 2025;25:201.
    PubMed     Abstract available
    
    
    
69. LI Y, Cao Y, Wang X, Li C, et al
    Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherap
    BMC Cancer. 2025;25:198.
    PubMed     Abstract available
    
    
    
70. ZHANG XQ, Huang ZN, Wu J, Zheng CY, et al
    Development and validation of a prognostic prediction model for elderly gastric cancer patients based on oxidative stress biochemical markers.
    BMC Cancer. 2025;25:188.
    PubMed     Abstract available
    
    
    January 2025
71. ZHONG B, Xiong Z, Zheng J, Mohamed SA, et al
    Impact of Helicobacter pylori infection on neoadjuvant chemotherapy in locally advanced gastric cancer: a retrospective analysis.
    BMC Cancer. 2025;25:157.
    PubMed     Abstract available
    
    
    
72. YUAN J, Jiang Y, Chen F, Li T, et al
    Clinical implications of DNA ploidy, stroma, and nucleotyping in predicting peritoneal metastasis risk for gastric cancer.
    BMC Cancer. 2025;25:144.
    PubMed     Abstract available
    
    
    
73. VARSHNEY N, Singh S, Kandpal M, Saini V, et al
    Interplay of aurora kinase a functional residues and Epstein-barr Nuclear Antigen 1 in Epstein-barr virus associated Gastric cancer using AGS cells.
    BMC Cancer. 2025;25:143.
    PubMed     Abstract available
    
    
    
74. LI Y, Ma J, Cheng W
    Harnessing Machine Learning and Nomogram Models to Aid in Predicting Progression-Free Survival for Gastric Cancer Patients Post-Gastrectomy with Deficient Mismatch Repair(dMMR).
    BMC Cancer. 2025;25:141.
    PubMed     Abstract available
    
    
    
75. NAJAFI S, Mohammadkhah F, Salemi SA, Kamyab A, et al
    The impact of educational intervention based on the theory of planned behavior on preventive behaviors for gastric cancer in obese and smoking individuals.
    BMC Cancer. 2025;25:129.
    PubMed     Abstract available
    
    
    
76. SOWELL FG, de Milliano T, Brady KJS, Foglia G, et al
    A conceptual model for advanced/metastatic gastric or gastroesophageal junction cancer: a review of qualitative studies and results from patient interviews.
    BMC Cancer. 2025;25:88.
    PubMed     Abstract available
    
    
    
77. XIAO Y, Zhu J, Xie H, Wang Z, et al
    Intratumoral and peritumoral radiomics for forecasting microsatellite status in gastric cancer: a multicenter study.
    BMC Cancer. 2025;25:66.
    PubMed     Abstract available
    
    
    
78. YEKTAKOOSHALI MH, SobhZahedi M, Razavi Tousi SMT, Hamidi M, et al
    Astaxanthin-loaded PLGA nanoparticles inhibit survival of MKN-45 gastric cancer cell line by modulating JAK2/STAT3/mTOR/PI3K pathway.
    BMC Cancer. 2025;25:44.
    PubMed     Abstract available
    
    
    
79. YIN C, Sun Y, Liang J, Sui X, et al
    Sedated and unsedated gastroscopy has no influence on the outcomes of patients with gastric cancer: a retrospective study.
    BMC Cancer. 2025;25:13.
    PubMed     Abstract available
    
    
    
80. YU X, Shao Y, Dong H, Yan J, et al
    Molecular subtype of gastric cancer based on apoptosis-related genes reveals differential immune microenvironment and intratumoral microorganisms distribution.
    BMC Cancer. 2025;25:12.
    PubMed     Abstract available
    
    
    December 2024
81. ZHANG YT, Wang SH, Zhao L, Wang HM, et al
    Screening and identification of vascular endothelial cell targeting peptide in gastric cancer through novel integrated in vitro and in vivo strategy.
    BMC Cancer. 2024;24:1595.
    PubMed     Abstract available
    
    
    
82. IITAKA S, Kuroda A, Narita T, Hatakeyama H, et al
    Evaluation of N-NOSE as a surveillance tool for recurrence in gastric and esophageal cancers: a prospective cohort study.
    BMC Cancer. 2024;24:1544.
    PubMed     Abstract available
    
    
    
83. MUDIYANSELAGE SB, Nguyen D, Tang B, Williams R, et al
    The epidemiological trends and predictions of esophageal squamous cell carcinoma and gastroesophageal junction carcinoma: an Australian population-based study.
    BMC Cancer. 2024;24:1498.
    PubMed     Abstract available
    
    
    
84. LUO D, Xu H, Jiang C, Zheng J, et al
    Knowledge, attitudes, and practices of primary caregivers of gastric cancer patients regarding postoperative dietary management.
    BMC Cancer. 2024;24:1487.
    PubMed     Abstract available
    
    
    
85. BRODKIN J, Kaprio T, Hagstrom J, Leppa A, et al
    Prognostic effect of immunohistochemically determined molecular subtypes in gastric cancer.
    BMC Cancer. 2024;24:1482.
    PubMed     Abstract available
    
    
    November 2024
86. TIAN Y, Qiu S, Yang S, Jiang Y, et al
    The oncogenic role and prognostic value of PXDN in human stomach adenocarcinoma.
    BMC Cancer. 2024;24:1463.
    PubMed     Abstract available
    
    
    
87. YU Z, Liang C, Li R, Xu Q, et al
    The impact of diabetes mellitus on short and long term outcomes in patients with gastric cancer following radical surgery: a retrospective cohort study with propensity score matching.
    BMC Cancer. 2024;24:1461.
    PubMed     Abstract available
    
    
    
88. LIU SS, Wang JK, Liu MS, Guo DF, et al
    ILF2 protein is a promising serum biomarker for early detection of gastric cancer.
    BMC Cancer. 2024;24:1447.
    PubMed     Abstract available
    
    
    
89. ABDI E, Latifi-Navid S, Kholghi-Oskooei V, Mostafaiy B, et al
    Roles of the lncRNAs MEG3, PVT1 and H19 tagSNPs in gastric cancer susceptibility.
    BMC Cancer. 2024;24:1440.
    PubMed     Abstract available
    
    
    
90. ZHANG H, Yang W, Tan X, He W, et al
    Long-term relative survival of patients with gastric cancer from a large-scale cohort: a period-analysis.
    BMC Cancer. 2024;24:1420.
    PubMed     Abstract available
    
    
    
91. MIYAMOTO H, Toyokawa T, Ishidate T, Kuroda K, et al
    Significance of the geriatric nutritional risk index and neutrophil-to-lymphocyte ratio as prognostic indicators in older patients with gastric cancer: a retrospective cohort study.
    BMC Cancer. 2024;24:1396.
    PubMed     Abstract available
    
    
    
92. HE L, Gao X, Li T, Li X, et al
    Multicriteria optimization achieves superior normal tissue sparing in volumetric modulated arc therapy for gastric cancer.
    BMC Cancer. 2024;24:1376.
    PubMed     Abstract available
    
    
    October 2024
93. LIU Y, Yang X, Wang Y, Xie S, et al
    Efficacy and safety of surufatinib in the treatment of patients with neuroendocrine tumor: a real-world study in Chinese population.
    BMC Cancer. 2024;24:1342.
    PubMed     Abstract available
    
    
    
94. NIU X, Ma F, Li F, Wei C, et al
    Integration of bioinformatics and cellular experiments unveils the role of SYT12 in gastric cancer.
    BMC Cancer. 2024;24:1331.
    PubMed     Abstract available
    
    
    
95. LIU YY, Tsai MY, Liu TT, Liu YW, et al
    The real-world efficacy and safety of nivolumab plus chemotherapy in patients with HER2-negative advanced gastric cancer.
    BMC Cancer. 2024;24:1325.
    PubMed     Abstract available
    
    
    
96. SUN Y, Chen C, Hou L, Zhao E, et al
    Short-term outcomes and quality of life of esophagogastrostomy versus the double-tract reconstruction after laparoscopic proximal gastrectomy.
    BMC Cancer. 2024;24:1324.
    PubMed     Abstract available
    
    
    
97. LI J, Ding F, Zhang S, Jia Y, et al
    Continuation of same programmed death-1 inhibitor regime beyond progression is a novel option for advanced gastric cancer.
    BMC Cancer. 2024;24:1292.
    PubMed     Abstract available
    
    
    
98. YANG X, Zeng Z, Liao Z, Zhu C, et al
    Comparison of proximal gastrectomy and total gastrectomy in proximal gastric cancer: a meta-analysis of postoperative health condition using the PGSAS-45.
    BMC Cancer. 2024;24:1282.
    PubMed     Abstract available
    
    
    September 2024
99. LIU F, Hu N, Jiang K, Liu H, et al
    Mutational signatures in 175 Chinese gastric cancer patients.
    BMC Cancer. 2024;24:1208.
    PubMed     Abstract available
    
    
    
100. LIU ZK, Ma WX, Zhang JJ, Liu SD, et al
     Risk factor analysis and establishment of a predictive model for complications of elderly advanced gastric cancer with Clavien-Dindo classification >/= II grade.
     BMC Cancer. 2024;24:1185.
     PubMed     Abstract available
     
     
     
101. ZHENG HL, Zhang LK, Lv CB, Xu BB, et al
     Impact of dynamic changes of tumor marker in neoadjuvant chemotherapy-treated triple-negative gastric cancer patients: a multi-center study.
     BMC Cancer. 2024;24:1188.
     PubMed     Abstract available
     
     
     
102. FU L, Song L, Zhou X, Chen L, et al
     Serum metabolomics analysis of malnutrition in patients with gastric cancer: a cross sectional study.
     BMC Cancer. 2024;24:1195.
     PubMed     Abstract available
     
     
     
103. LUAN X, Zhao L, Zhang F, Wang W, et al
     Sex disparity, prediagnosis lifestyle factors, and long-term survival of gastric cancer: a multi-center cohort study from China.
     BMC Cancer. 2024;24:1149.
     PubMed     Abstract available
     
     
     
104. HE H, Dong K, Chen M, Wang Y, et al
     TOB1 inhibits the gastric cancer progression by focal adhesion pathway and ERK pathway based on transcriptional and metabolic sequencing.
     BMC Cancer. 2024;24:1130.
     PubMed     Abstract available
     
     
     
105. INUKAI M, Nishi T, Matsuoka H, Matsuo K, et al
     Measurement of changes in serum-based inflammatory indicators to monitor response to nivolumab monotherapy in advanced gastric cancer: a multicenter retrospective study.
     BMC Cancer. 2024;24:1121.
     PubMed     Abstract available
     
     
     
106. CHEN D, Tong W, Ang B, Bai Y, et al
     Revealing the crosstalk between LOX(+) fibroblast and M2 macrophage in gastric cancer by single-cell sequencing.
     BMC Cancer. 2024;24:1117.
     PubMed     Abstract available
     
     
     
107. LUO D, Xu H, Jiang C, Zheng J, et al
     The prognostic role of palliative gastrectomy in advanced gastric cancer: a systematic review and meta-analysis.
     BMC Cancer. 2024;24:1096.
     PubMed     Abstract available
     
     
     
108. GOKON Y, Nakashima Y, Ohki Y, Ogino T, et al
     Prognostic significance of low HER2 expression in gastric cancer: a retrospective, single-center analysis.
     BMC Cancer. 2024;24:1081.
     PubMed     Abstract available
     
     
     August 2024
109. WANG Y, Lei X, Shan F, Li S, et al
     Long-term outcomes of laparoscopic versus open total gastrectomy in patients with advanced gastric cancer after neoadjuvant chemotherapy: a retrospective cohort study.
     BMC Cancer. 2024;24:1074.
     PubMed     Abstract available
     
     
     
110. WANG Y, Li W, Zhou CM, Zhao Z, et al
     Mortality risk of patients with intestinal obstruction.
     BMC Cancer. 2024;24:1062.
     PubMed     Abstract available
     
     
     
111. CHEN Z, Zhang G, Liu Y, Zhu K, et al
     Radiomics analysis in predicting vascular invasion in gastric cancer based on enhanced CT: a preliminary study.
     BMC Cancer. 2024;24:1020.
     PubMed     Abstract available
     
     
     
112. JIANG X, Qin L, Hao Y, Yang Q, et al
     The staining results of early gastric cancer by indigo carmine chromoendoscopy associated with histological structure: a retrospective study.
     BMC Cancer. 2024;24:1015.
     PubMed     Abstract available
     
     
     
113. DING P, Yang J, Wu J, Wu H, et al
     Combined systemic inflammatory immune index and prognostic nutrition index as chemosensitivity and prognostic markers for locally advanced gastric cancer receiving neoadjuvant chemotherapy: a retrospective study.
     BMC Cancer. 2024;24:1014.
     PubMed     Abstract available
     
     
     
114. XU L, Liu J, An Y, Zhou L, et al
     Glycolysis-related genes predict prognosis and indicate immune microenvironment features in gastric cancer.
     BMC Cancer. 2024;24:979.
     PubMed     Abstract available
     
     
     
115. XIAO H, Fu J, Liu R, Yan L, et al
     Gastric cancer cell-derived exosomal miR-541-5p induces M2 macrophage polarization through DUSP3/JAK2/STAT3 pathway.
     BMC Cancer. 2024;24:957.
     PubMed     Abstract available
     
     
     July 2024
116. WU Q, Li T, Cui Y, Jiang H, et al
     Unveiling clinicopathologic features and outcomes for endoscopic submucosal dissection of early gastric cancer at gastric angulus in China.
     BMC Cancer. 2024;24:924.
     PubMed     Abstract available
     
     
     June 2024
117. ZENG Z, Li Y, Zhou H, Li M, et al
     System-wide identification of novel de-ubiquitination targets for USP10 in gastric cancer metastasis through multi-omics screening.
     BMC Cancer. 2024;24:773.
     PubMed     Abstract available
     
     
     
118. ENDO S, Higashida M, Furuya K, Yano S, et al
     Prognostic factors for gastric cancer patients aged >/= 85 years.
     BMC Cancer. 2024;24:745.
     PubMed     Abstract available
     
     
     
119. YU M, Peng J, Lu Y, Li S, et al
     Silencing immune-infiltrating biomarker CCDC80 inhibits malignant characterization and tumor formation in gastric cancer.
     BMC Cancer. 2024;24:724.
     PubMed     Abstract available
     
     
     
120. ICHIKAWA H, Usui K, Aizawa M, Shimada Y, et al
     Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer.
     BMC Cancer. 2024;24:719.
     PubMed     Abstract available
     
     
     
121. ZHANG S, Xu H, Li W, Cui J, et al
     Development and validation of an inflammatory biomarkers model to predict gastric cancer prognosis: a multi-center cohort study in China.
     BMC Cancer. 2024;24:711.
     PubMed     Abstract available
     
     
     
122. LI X, Wang C, Wang Y, Chen X, et al
     Integrated analysis of the role of PR/SET domain 14 in gastric cancer.
     BMC Cancer. 2024;24:685.
     PubMed     Abstract available
     
     
     
123. YE J, Ying J, Chen H, Wu Z, et al
     PPIH acts as a potential predictive biomarker for patients with common solid tumors.
     BMC Cancer. 2024;24:681.
     PubMed     Abstract available
     
     
     May 2024
124. WANG J, Lin J, Wang R, Tong T, et al
     Immunotherapy combined with apatinib in the treatment of advanced or metastatic gastric/gastroesophageal tumors: a systematic review and meta-analysis.
     BMC Cancer. 2024;24:603.
     PubMed     Abstract available
     
     
     
125. PANG H, Dai L, Chen L, Chen X, et al
     Prognostic value of the advanced lung cancer inflammation index in patients with gastric cancer after radical gastrectomy: a propensity-score matching cohort study and meta-analysis.
     BMC Cancer. 2024;24:583.
     PubMed     Abstract available
     
     
     
126. CHE B, Yuan S, Zhang H, Zhai J, et al
     Causal inference between pernicious anemia and cancers: a bidirectional two-sample mendelian randomization analysis.
     BMC Cancer. 2024;24:586.
     PubMed     Abstract available
     
     
     
127. WANG S, Zhang W, Wu X, Zhu Z, et al
     Comprehensive analysis of T-cell regulatory factors and tumor immune microenvironment in stomach adenocarcinoma.
     BMC Cancer. 2024;24:570.
     PubMed     Abstract available
     
     
     April 2024
128. ZHAN Z, Chen B, Cheng H, Xu S, et al
     Identification of prognostic signatures in remnant gastric cancer through an interpretable risk model based on machine learning: a multicenter cohort study.
     BMC Cancer. 2024;24:547.
     PubMed     Abstract available
     
     
     
129. CHOI Y, Lee J, Shin K, Lee JW, et al
     Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer.
     BMC Cancer. 2024;24:502.
     PubMed     Abstract available
     
     
     
130. TAN Y, Feng LJ, Huang YH, Xue JW, et al
     Correction: Development and validation of a Radiopathomics model based on CT scans and whole slide images for discriminating between Stage I-II and Stage III gastric cancer.
     BMC Cancer. 2024;24:469.
     PubMed    
     
     
     
131. LIU SS, Wan QS, Lv C, Wang JK, et al
     Integrating trans-omics, cellular experiments and clinical validation to identify ILF2 as a diagnostic serum biomarker and therapeutic target in gastric cancer.
     BMC Cancer. 2024;24:465.
     PubMed     Abstract available
     
     
     
132. LUNA J, Picker N, Wilke T, Lutz M, et al
     Real-world evidence of treatment patterns and survival of metastatic gastric cancer patients in Germany.
     BMC Cancer. 2024;24:462.
     PubMed     Abstract available
     
     
     
133. LI F, Dou J, Wei L, Li S, et al
     Biomarkers of lipid metabolism in gastric cancer: a case control study.
     BMC Cancer. 2024;24:455.
     PubMed     Abstract available
     
     
     
134. ZHONG Y, Xiao YY, Ye JY, Jian GL, et al
     Diagnostic efficacy of contrast-enhanced gastric ultrasonography in staging gastric cancer: a meta-analysis.
     BMC Cancer. 2024;24:422.
     PubMed     Abstract available
     
     
     
135. ZHAN PC, Yang S, Liu X, Zhang YY, et al
     A radiomics signature derived from CT imaging to predict MSI status and immunotherapy outcomes in gastric cancer: a multi-cohort study.
     BMC Cancer. 2024;24:404.
     PubMed     Abstract available
     
     
     March 2024
136. YOON C, Lu J, Jun Y, Suh YS, et al
     Retraction Note: KRAS activation in gastric cancer stem-like cells promotes tumor angiogenesis and metastasis.
     BMC Cancer. 2024;24:392.
     PubMed    
     
     
     
137. TAN Y, Feng LJ, Huang YH, Xue JW, et al
     Development and validation of a Radiopathomics model based on CT scans and whole slide images for discriminating between Stage I-II and Stage III gastric cancer.
     BMC Cancer. 2024;24:368.
     PubMed     Abstract available
     
     
     
138. LIU D, Quan H, Ma M, Zhou H, et al
     Nomogram to predict overall survival of patients receiving radical gastrectomy and incomplete peri-operative adjuvant chemotherapy for stage II/III gastric cancer: a retrospective bi-center cohort study.
     BMC Cancer. 2024;24:344.
     PubMed     Abstract available
     
     
     
139. CHEN Y, Chen X, Lin Y, Zhang S, et al
     Correction: Oncological risk of proximal gastrectomy for proximal advanced gastric cancer after neoadjuvant chemotherapy.
     BMC Cancer. 2024;24:314.
     PubMed    
     
     
     
140. WANG J, Shao M, Hu H, Xiao W, et al
     Convolutional neural network applied to preoperative venous-phase CT images predicts risk category in patients with gastric gastrointestinal stromal tumors.
     BMC Cancer. 2024;24:280.
     PubMed     Abstract available
     
     
     February 2024
141. ZHANG J, Wang L, Zhang S, Cao R, et al
     Alpha-fetoprotein predicts the treatment efficacy of immune checkpoint inhibitors for gastric cancer patients.
     BMC Cancer. 2024;24:266.
     PubMed     Abstract available
     
     
     
142. CHEN Y, Chen X, Lin Y, Zhang S, et al
     Oncological risk of proximal gastrectomy for proximal advanced gastric cancer after neoadjuvant chemotherapy.
     BMC Cancer. 2024;24:255.
     PubMed     Abstract available
     
     
     
143. LIM SH, Lee KW, Kim JJ, Im HS, et al
     Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06).
     BMC Cancer. 2024;24:252.
     PubMed     Abstract available
     
     
     
144. LI ZZ, Yan XL, Zhang Z, Chen JL, et al
     Prognostic value of GLIM-defined malnutrition in combination with hand-grip strength or gait speed for the prediction of postoperative outcomes in gastric cancer patients with cachexia.
     BMC Cancer. 2024;24:253.
     PubMed     Abstract available
     
     
     
145. DE MORAES FCA, Pasqualotto E, Chavez MP, Ferreira ROM, et al
     Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials.
     BMC Cancer. 2024;24:240.
     PubMed     Abstract available
     
     
     
146. SUI H, Lou A, Li Z, Yang J, et al
     Retraction Note: Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145.
     BMC Cancer. 2024;24:241.
     PubMed    
     
     
     
147. ZHENG HL, Wang FH, Zhang LK, Li P, et al
     Trajectories of neutrophil-to-lymphocyte ratios during neoadjuvant chemotherapy correlate with short- and long-term outcomes in gastric cancer: a group-based trajectory analysis.
     BMC Cancer. 2024;24:226.
     PubMed     Abstract available
     
     
     
148. FARAMARZI S, Kiani B, Faramarzi S, Firouraghi N, et al
     Cancer patterns in Iran: a gender-specific spatial modelling of cancer incidence during 2014-2017.
     BMC Cancer. 2024;24:191.
     PubMed     Abstract available
     
     
     January 2024
149. HONG Z, Wen P, Wang K, Wei X, et al
     The macrophage-associated prognostic gene ANXA5 promotes immunotherapy resistance in gastric cancer through angiogenesis.
     BMC Cancer. 2024;24:141.
     PubMed     Abstract available
     
     
     
150. WEI L, Wu X, Wang L, Chen L, et al
     Expression and prognostic value of APOBEC2 in gastric adenocarcinoma and its association with tumor-infiltrating immune cells.
     BMC Cancer. 2024;24:15.
     PubMed     Abstract available
     
     
     
151. QU T, Zhang S, Yang S, Li S, et al
     Utilizing serum metabolomics for assessing postoperative efficacy and monitoring recurrence in gastric cancer patients.
     BMC Cancer. 2024;24:27.
     PubMed     Abstract available
     
     
     December 2023
152. ZHU G, Cai H, Xiao Q, Zeng S, et al
     GRB7 plays a promoting role in the progression of gastric cancer.
     BMC Cancer. 2023;23:1262.
     PubMed     Abstract available
     
     
     
153. CHE J, Zhao Y, Gu B, Li S, et al
     Untargeted serum metabolomics reveals potential biomarkers and metabolic pathways associated with the progression of gastroesophageal cancer.
     BMC Cancer. 2023;23:1238.
     PubMed     Abstract available
     
     
     
154. NIE C, Xu W, Guo Y, Gao X, et al
     Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study.
     BMC Cancer. 2023;23:1239.
     PubMed     Abstract available
     
     
     
155. GAO J, Lan J, Liao H, Yang F, et al
     Promising preclinical patient-derived organoid (PDO) and xenograft (PDX) models in upper gastrointestinal cancers: progress and challenges.
     BMC Cancer. 2023;23:1205.
     PubMed     Abstract available
     
     
     
156. BOBRZYNSKI L, Sedlak K, Rawicz-Pruszynski K, Kolodziejczyk P, et al
     Evaluation of optimum classification measures used to define textbook outcome among patients undergoing curative-intent resection of gastric cancer.
     BMC Cancer. 2023;23:1199.
     PubMed     Abstract available
     
     
     
157. JEON CH, Park KB, Lee H, Kim DJ, et al
     Refining gastric cancer staging: examining the interplay between number and anatomical location of metastatic lymph nodes - a retrospective multi-institutional study.
     BMC Cancer. 2023;23:1192.
     PubMed     Abstract available
     
     
     November 2023
158. WEI C, He Y, Luo M, Chen G, et al
     The role of computed tomography features in assessing response to neoadjuvant chemotherapy in locally advanced gastric cancer.
     BMC Cancer. 2023;23:1157.
     PubMed     Abstract available
     
     
     
159. ZHENG H, Yin X, Pan T, Tao X, et al
     Effect of different surgical approaches on the survival and safety of Siewert type II esophagogastric junction adenocarcinoma: a systematic review and meta-analysis.
     BMC Cancer. 2023;23:1130.
     PubMed     Abstract available
     
     
     
160. CHEN YY, Li BP, Wang JF, Wang Y, et al
     Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer.
     BMC Cancer. 2023;23:1122.
     PubMed     Abstract available
     
     
     
161. LIU X, Ren J, Zhou R, Wen Z, et al
     Construction of iron metabolism-related prognostic features of gastric cancer based on RNA sequencing and TCGA database.
     BMC Cancer. 2023;23:1106.
     PubMed     Abstract available
     
     
     
162. YANG Y, Li Y, Chen Z
     Impact of low serum iron on treatment outcome of PD-1 inhibitors in advanced gastric cancer.
     BMC Cancer. 2023;23:1095.
     PubMed     Abstract available
     
     
     
163. TAKASHIMA Y, Komatsu S, Nishibeppu K, Ohashi T, et al
     A shorter distal resection margin is a surrogate marker of nodal metastasis and poor prognosis in distal gastrectomy for advanced gastric cancer.
     BMC Cancer. 2023;23:1075.
     PubMed     Abstract available
     
     
     October 2023
164. LUKSTA M, Bausys A, Bickaite K, Rackauskas R, et al
     Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in combination with FOLFOX chemotherapy as a first-line treatment for gastric cancer patients with peritoneal metastases: single-arm phase II study.
     BMC Cancer. 2023;23:1032.
     PubMed     Abstract available
     
     
     
165. QYI YZ, Aung HH, Aye SN, Tung WS, et al
     Toll-like receptor 9 (-1237 T/C, -1486 T/C) and the risk of gastric cancer: a meta-analysis of genetic association studies.
     BMC Cancer. 2023;23:1027.
     PubMed     Abstract available
     
     
     
166. SUN C, Niu P, Zhang X, Zhao L, et al
     Concurrent clinical and pathological response predicts favorable prognosis of patients with gastric cancer after neoadjuvant therapy: a real-world study.
     BMC Cancer. 2023;23:996.
     PubMed     Abstract available
     
     
     
167. MAKUUCHI R, Terashima M, Terada M, Mizusawa J, et al
     Randomized controlled phase III trial to investigate superiority of robot-assisted gastrectomy over laparoscopic gastrectomy for clinical stage T1-4aN0-3 gastric cancer patients (JCOG1907, MONA LISA study): a study protocol.
     BMC Cancer. 2023;23:987.
     PubMed     Abstract available
     
     
     
168. BEIHAGHI M, Sahebi R, Beihaghi MR, Nessiani RK, et al
     Evaluation of rs10811661 polymorphism in CDKN2A / B in colon and gastric cancer.
     BMC Cancer. 2023;23:985.
     PubMed     Abstract available
     
     
     
169. NARA K, Yamamoto T, Yamashita H, Yagi K, et al
     Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab the
     BMC Cancer. 2023;23:979.
     PubMed     Abstract available
     
     
     
170. WU D, Lu J, Xue Z, Zhong Q, et al
     Evaluation of dynamic recurrence risk for locally advanced gastric cancer in the clinical setting of adjuvant chemotherapy: a real-world study with IPTW-based conditional recurrence analysis.
     BMC Cancer. 2023;23:964.
     PubMed     Abstract available
     
     
     
171. WANG Y, Guo Z, Tian Y, Cong L, et al
     MAPK1 promotes the metastasis and invasion of gastric cancer as a bidirectional transcription factor.
     BMC Cancer. 2023;23:959.
     PubMed     Abstract available
     
     
     
172. XIANG L, Jin S, Yu Y, Wang D, et al
     Risk of venous thromboembolism in patients undergoing gastric cancer surgery: a systematic review and meta-analysis.
     BMC Cancer. 2023;23:933.
     PubMed     Abstract available
     
     
     
173. WANG Y, Pan J, An F, Chen K, et al
     GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer.
     BMC Cancer. 2023;23:925.
     PubMed     Abstract available
     
     
     
174. XIA B, Gu X, Xu T, Yan M, et al
     Exosomes-mediated transfer of LINC00691 regulates the formation of CAFs and promotes the progression of gastric cancer.
     BMC Cancer. 2023;23:928.
     PubMed     Abstract available
     
     
     September 2023
175. KIM Y, Bae YJ, Kim JH, Kim H, et al
     Wnt/beta-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells.
     BMC Cancer. 2023;23:922.
     PubMed     Abstract available
     
     
     
176. SUN Y, Chen C, Hou L, Zhao E, et al
     Short-term and long-term outcomes of patients with gastric cancer during versus before the COVID-19 pandemic: cohort study using propensity score matching method.
     BMC Cancer. 2023;23:913.
     PubMed     Abstract available
     
     
     
177. WU J, Tian S, Xu J, Cheng N, et al
     Association of high-risk comorbidity with overall survival among patients with gastric cancer and its sex-specific differences in China: a retrospective observational cohort study.
     BMC Cancer. 2023;23:916.
     PubMed     Abstract available
     
     
     
178. SAHIN MEH, Akbas F, Yardimci AH, Sahin E, et al
     The effect of sarcopenia and sarcopenic obesity on survival in gastric cancer.
     BMC Cancer. 2023;23:911.
     PubMed     Abstract available
     
     
     
179. MA X, Pierce E, Anand H, Aviles N, et al
     Early prediction of response to palliative chemotherapy in patients with stage-IV gastric and esophageal cancer.
     BMC Cancer. 2023;23:910.
     PubMed     Abstract available
     
     
     
180. ZHAO L, Zhang F, Jiao F, Zhou X, et al
     The minimum number of examined lymph nodes was 24 for optimal survival of pathological T2-4 gastric cancer: a multi-center, hospital-based study covering 20 years of data.
     BMC Cancer. 2023;23:892.
     PubMed     Abstract available
     
     
     August 2023
181. HIGUCHI S, Suehiro Y, Izuhara L, Yoshina S, et al
     BCL7B, a SWI/SNF complex subunit, orchestrates cancer immunity and stemness.
     BMC Cancer. 2023;23:811.
     PubMed     Abstract available
     
     
     
182. DI Y, Ding L, Gao L, Huang H, et al
     Association of meat consumption with the risk of gastrointestinal cancers: a systematic review and meta-analysis.
     BMC Cancer. 2023;23:782.
     PubMed     Abstract available
     
     
     
183. SHIH YH, Lin HC, Liao PW, Chou CW, et al
     The efficacy of adjuvant chemotherapy for older adults with stage II/III gastric cancer: a retrospective cohort study.
     BMC Cancer. 2023;23:770.
     PubMed     Abstract available
     
     
     
184. HAN Y, Wu J, Ji R, Tan H, et al
     Preoperative sarcopenia combined with prognostic nutritional index predicts long-term prognosis of radical gastrectomy with advanced gastric cancer: a comprehensive analysis of two-center study.
     BMC Cancer. 2023;23:751.
     PubMed     Abstract available
     
     
     
185. TAKAHASHI N, Hara H, Nagashima K, Hirata K, et al
     Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G).
     BMC Cancer. 2023;23:726.
     PubMed     Abstract available
     
     
     July 2023
186. YOON C, Lu J, Jun Y, Suh YS, et al
     KRAS activation in gastric cancer stem-like cells promotes tumor angiogenesis and metastasis.
     BMC Cancer. 2023;23:690.
     PubMed     Abstract available
     
     
     
187. YANAGIMOTO Y, Imamura H, Adachi S, Odagiri K, et al
     The effect of specimen processing time on HER2 expression in gastric cancer and esophagogastric junction cancer: a single-center retrospective observational study.
     BMC Cancer. 2023;23:645.
     PubMed     Abstract available
     
     
     June 2023
188. HAN Y, Wang X, Xu M, Teng Z, et al
     Aspartoacylase promotes the process of tumour development and is associated with immune infiltrates in gastric cancer.
     BMC Cancer. 2023;23:604.
     PubMed     Abstract available
     
     
     
189. JEON CH, Park KB, Kim S, Seo HS, et al
     Predictive model for long-term weight recovery after gastrectomy for gastric cancer: an introduction to a web calculator.
     BMC Cancer. 2023;23:580.
     PubMed     Abstract available
     
     
     
190. LORENZEN S, Schwarz A, Pauligk C, Goekkurt E, et al
     Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/I
     BMC Cancer. 2023;23:561.
     PubMed     Abstract available
     
     
     
191. SHEN X, Liu H, Zhou H, Cheng Z, et al
     Galectin-1 promotes gastric cancer peritoneal metastasis through peritoneal fibrosis.
     BMC Cancer. 2023;23:559.
     PubMed     Abstract available
     
     
     
192. TIAN Y, Pang Y, Yang PG, Guo HH, et al
     Clinical implications of micro lymph node metastasis for patients with gastric cancer.
     BMC Cancer. 2023;23:536.
     PubMed     Abstract available
     
     
     
193. E Y, Yu Q, Sun T, Xue H, et al
     The relationship between pepsinogen C and gastric carcinogenesis: a transgene and population study.
     BMC Cancer. 2023;23:520.
     PubMed     Abstract available
     
     
     
194. LI Y, Wu G, Liu J, Zhang Y, et al
     Log odds of positive lymph nodes as a novel prognostic predictor for gastric cancer: a systematic review and meta-analysis.
     BMC Cancer. 2023;23:523.
     PubMed     Abstract available
     
     
     
195. DU Y, Yu X, Chang ET, Yin L, et al
     EBV antibody and gastric cancer risk: a population-based nested case-control study in southern China.
     BMC Cancer. 2023;23:521.
     PubMed     Abstract available
     
     
     
196. ZHAO Z, Zhu Y
     FAP, CD10, and GPR77-labeled CAFs cause neoadjuvant chemotherapy resistance by inducing EMT and CSC in gastric cancer.
     BMC Cancer. 2023;23:507.
     PubMed     Abstract available
     
     
     May 2023
197. LEONG E, Ong SK, Si-Ramlee KA, Naing L, et al
     Cancer incidence and mortality in Brunei Darussalam, 2011 to 2020.
     BMC Cancer. 2023;23:466.
     PubMed     Abstract available
     
     
     
198. XU D, Liu X, Ke S, Guo Y, et al
     CCL19/CCR7 drives regulatory T cell migration and indicates poor prognosis in gastric cancer.
     BMC Cancer. 2023;23:464.
     PubMed     Abstract available
     
     
     
199. ZHANG H, Wang H, Ye L, Bao S, et al
     Comprehensive transcriptomic analyses identify KDM genes-related subtypes with different TME infiltrates in gastric cancer.
     BMC Cancer. 2023;23:454.
     PubMed     Abstract available
     
     
     
200. HAMADA T, Higashi M, Yokoyama S, Akahane T, et al
     MALAT1 functions as a transcriptional promoter of MALAT1::GLI1 fusion for truncated GLI1 protein expression in cancer.
     BMC Cancer. 2023;23:424.
     PubMed     Abstract available
     
     
     
201. YANG H, Wang JB, Wang XK, Fan JH, et al
     Association between type of drinking water and upper gastrointestinal cancer incidence in the Linxian General Population.
     BMC Cancer. 2023;23:397.
     PubMed     Abstract available
     
     
     April 2023
202. LIU Y, Shen S, Yan Z, Yan L, et al
     Expression characteristics and their functional role of IGFBP gene family in pan-cancer.
     BMC Cancer. 2023;23:371.
     PubMed     Abstract available
     
     
     
203. CUI Y, Yu Y, Zheng S, Ying J, et al
     Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? a multicenter, prospective cohort study (Neo-REGATTA).
     BMC Cancer. 2023;23:308.
     PubMed     Abstract available
     
     
     March 2023
204. WANG H, Cui H, Yang X, Peng L, et al
     TUBA1C: a new potential target of LncRNA EGFR-AS1 promotes gastric cancer progression.
     BMC Cancer. 2023;23:258.
     PubMed     Abstract available
     
     
     
205. YANG J, Li J, Deng Q, Chen Z, et al
     Effect of neoadjuvant chemotherapy combined with arterial chemoembolization on short-term clinical outcome of locally advanced gastric cancer.
     BMC Cancer. 2023;23:246.
     PubMed     Abstract available
     
     
     
206. KAMIYA H, Komatsu S, Nishibeppu K, Ohashi T, et al
     Evaluating prognostic value and stage migration effects using a positive lymph node ratio in adenocarcinoma of the esophagogastric junction.
     BMC Cancer. 2023;23:218.
     PubMed     Abstract available
     
     
     
207. ZHANG L, Wang W, Ge S, Li H, et al
     Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial.
     BMC Cancer. 2023;23:211.
     PubMed     Abstract available
     
     
     February 2023
208. XIAO H, Bertwistle D, Khela K, Middleton-Dalby C, et al
     Global retrospective analysis of clinician- and patient-reported clinical characteristics and humanistic burden of patients with gastroesophageal cancers on first-line treatment.
     BMC Cancer. 2023;23:186.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Gastric Cancer is free of charge.